The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...
Zacks Investment Research on MSN
Eli Lilly or Merck: Where should investors put their money?
Eli Lilly LLY and Merck MRK are both major global pharmaceutical companies with blockbuster drug portfolios and deep ...
Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through its LillyDirect platform.
Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...
Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S.
US pharma major Eli Lilly (NYSE: LLY) has lowered the price of Zepbound (tirzepatide) single-dose vials on its Lilly Direct platform, widening access in a fast-moving obesity market. The 2.5-mg ...
Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...
Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple ...
President Donald Trump announced a new agreement with Eli Lilly and Novo Nordisk to expand coverage and lower prices for popular obesity drugs Zepbound and Wegovy, part of the GLP-1 class of ...
Eli Lilly has lowered the price of its GLP-1 drug Zepbound (tirzepatide) in single-dose vials, with the starting dose now available for $299 per month through the company’s direct-to-consumer platform ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback